Collectively, these data indicate that PRAME is well expressed in a diversity of tumors exhibiting oncogenic mutations or cellular and molecular features associated with sensitivity or resistance to immune checkpoint inhibitors, e.g. tumor mutation burden or immune infiltration. This evidence concerns the gene PRAME and neoplasm.